• VIDEO: ‘Interesting' Lung-MAP substudy data at ASCO

    10 days ago - By Healio

    In this video, Jia Luo, MD, highlighted a phase 2 randomized study in non-small cell lung cancer presented at ASCO Annual Meeting.
    “What was interesting was the patients were randomized to pembrolizumab plus ramucirumab , which is a VGEF inhibitor, vs. standard-of-care chemotherapy,” Luo, thoracic medical oncologist and cancer researcher with Dana-Farber and Harvard Medical School, said.
    Read more ...